Effects of continuous or pulsed exposure to rifabutin and sparfloxacin on the intracellular growth of Staphylococcus aureus and Mycobacterium tuberculosis

Journal of Chemotherapy

Volumn 13, Issue 2, 2001, Pages 167-175

  Fietta, A ^a   Morosini, M ^a   Cascina, A ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Intracellular bioactivity; Intracellular PAE; M. tuberculosis; Rifabutin; S. aureus; Sparfloxacin

Indexed keywords

RIFABUTIN; SPARFLOXACIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; POSTANTIBIOTIC EFFECT; PULSATILE FLOW; STAPHYLOCOCCUS AUREUS;

EID: 0035054381     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2001.13.2.167     Document Type: Article

References (30)

1. Intracellular organisms
2. Intracellular activity, potential clinical uses of antibiotics
3. Optimum treatment of intracellular infection
4. Nouveautès en pharmacologie clinique des agents antiinfectieux
5. Biological activity of a new class of rifamycins: Spiro-piperidyl-rifamycins
6. In vitro and in vivo antibacterial activity of AM-1155, a new 6-fluoro-8-methoxy quinolone
7. Uptake and intracellular activity of AM-1155 in phagocytic cells
8. Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells
9. Le interazioni tra antibiotici e fagociti
10. Comparison of the activity of fluoroquinolones against Mycobacterium avium in cell-free systems and in human monocyte in-vitro infection model
11. Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi
12. Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium
13. In vitro extracellular and intracellular activity of two newer and two earlier fluoroquinolones against Listeria monocytogenes
14. In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combination of two, three, and four drugs against Mycobacterium avium
15. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium
16. In vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli
17. In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species
18. Inhibition of intracellular growth of Staphylococcus aureus by exposure of infected human monocytes to clarithromycin and azithromycin
19. Pharmacokinetics of rifabutin
20. Single and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans
21. Rifabutin (ansamycin LM 427): A new rifamycin-S derivative for the treatment of mycobacterial diseases
22. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses
23. Global surveillance for antituberculosis drug resistance in 1994-1997
24. Surveillance of antibiotic resistance
25. A Dutch approach to methicillin-resistant Staphylococcus aureus
26. Rifabutin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy
27. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells
28. Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells
29. Uptake and subcellular localization of sparfloxacin (AT-4140, RP-64206; S) in phagocytic cells
30. Tissue-directed antibiotic therapy: Antibiotic dynamics in cells and tissues. Challenges to antibiotic activity in tissue